The Global Necrotising Enterocolitis Market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the Necrotising Enterocolitis (NEC) Market is expected to register a CAGR 5.5% during the forecast period of 2018 to 2023.
Necrotizing Enterocolitis is the most common cause of gastrointestinal-related morbidity and mortality. The most premature infants are the most vulnerable. According to a study published in the Advances in Neonatal Care (2013), it was estimated that approximately 12% of infants born with the body weight of less than 1500 g are likely to develop Necrotizing Enterocolitis. The ascites condition is also found to be associated with Stage IIa and IIIa. The severity of the condition pushes the demand for better diagnosis and treatment approaches. Notably, the market is expected to expand in the near future due to the prevalence of Necrotizing Enterocolitis.
Get Exclusive Sample Copy @ https://www.marketresearchfuture.com/sample_request/5999 .
Various other factors such as improved reimbursement policies in developed countries, improving regulatory framework, growing research funding, unmet medical needs, and increasing government assistance are continuously contributing to the growth of the global Necrotising Enterocolitis (NEC) market. The increasing contribution of marketers is also fueling the growth of the market. For instance, on February 15, 2018, Prometic Life Sciences Inc. received the FDA orphan drug designation status to its Inter-Alpha-Inhibitor-Proteins (“IAIP”) for the treatment of necrotizing enterocolitis.
List of Major Players Mentioned in Report:
The Global Necrotising Enterocolitis (NEC) Market Players are Abbott Laboratories Inc. (U.S.), Astellas Pharma Inc. (Japan), Bayer HealthCare AG (Germany), Becton, Dickinson and Company (BD) (U.S.), Bristol-Myers Squibb Company (U.S.), Daiichi Sankyo Company , Ltd. (Japan), Eli Lilly and Co. (U.S.), Enzon Pharmaceuticals, Inc. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), GI Supply (U.S.), GlaxoSmithKline Plc (UK), Kyorin Pharmaceutical Co., Ltd. (U.S.), Medtronic Plc (U.S.), Merck & Co. Inc. (U.S.), MiddleBrook Pharmaceuticals (Japan), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Sanofi-Aventis (France), Sequana Medical AG (Switzerland), Takeda Pharmaceutical Company, Ltd. (Japan), and others.
Necrotising Enterocolitis (NEC) Market Segmentation:
The Global Necrotising Enterocolitis (NEC) Market is segmented on the basis of stage, diagnosis, treatment, and end-user.
Based on stage, the market is classified as Stage I, Stage II, and Stage III. The Stage II is further segmented into Stage IIa and Stage IIb. The Stage III is further segmented into Stage IIIa and Stage IIIb.
Based on diagnosis, the market is classified as imaging, laboratory studies, and differential diagnosis. The imaging segment is further classified as abdominal x-ray, Magnetic Resonance Imaging (MRI), ultrasound, laparoscopy, angiography, and others. The laboratory studies segment is further classified as haemochromocytometric exam, blood culture, serum electrolytes, arterial blood gas analysis, blood pressure monitor, and others. The differential diagnosis segment is further classified as ileus secondary to neonatal sepsis, spontaneous intestinal perforation, ileal atresia, intestinal malrotation, volvulus, neonatal appendicitis, neonatal pseudomembranous colitis, and others.
Based on treatment, the market is classified as Total Parenteral Nutrition (TPN), gastrointestinal decompression, antimicrobial therapy, antifungal treatment, paracentesis, and others.
Based on end-user, the market is classified as hospitals and clinics, ambulatory surgical center, diagnostic centers, and others.
Necrotising Enterocolitis (NEC) Market Regional Summary:
The Americas dominates the Necrotising Enterocolitis (NEC) market owing to the increasing prevalence of chronic pain, well-developed technology, high healthcare expenditure, and the presence of leading players. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the U.S. region was reported to be USD 3.2 trillion hospital care accounted for a share of 32.3%.
Europe holds the second position in the Necrotising Enterocolitis (NEC) market. It is expected that the increasing contribution towards research and development and increasing competition among marketers are likely to drive the European Necrotising Enterocolitis (NEC) market.
Asia Pacific is the fastest growing Necrotising Enterocolitis (NEC) market owing to a huge patient pool, increasing demand for treatment, and rising healthcare expenditure. As per the data suggested by the Australian Institute of Health and Welfare during 2015 to 2016, the total health expenditure was nearly USD 170.4 billion, i.e., 3.6% higher than the expenditure of 2014 to 2015.
The Middle East and Africa holds the lowest share of the global Necrotising Enterocolitis (NEC) market due to low development, lack of technical knowledge, and poor medical facilities.
Ask Questions to Experts @ https://www.marketresearchfuture.com/enquiry/5999 .
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: Send Email
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar